CABR

Caring Brands is a development-stage wellness/cosmetics company that generated $4,215 of revenue in all of FY2025 against a $6.28M net loss — a P/S of ~3,953x that is meaningless because there is effectively no business yet. The MD&A concedes the company 'is still in process of developing and commercializing its products'; the OTC/cosmetic pipeline (hair-loss, eczema/psoriasis, vitiligo, jellyfish-sting suncare) is pre-commercial, and FY2025 R&D was literally $0. Operating expenses of $5.94M were dominated not by product development but by $2.55M of intellectual-property impairment, $2.0M of payroll, $0.93M of professional/legal/advisory fees, and $0.30M of license amortization — i.e., the cost of being a newly NASDAQ-listed public shell, not of building a franchise. The impairment is the tell: management determined the carrying value of its core IP license 'was no longer recoverable,' and it wrote down another $500K on an investment.

The capital structure and history compound the risk. This is a reverse merger (note the Predecessor/Successor split at Sept 24-25, 2024), so there is no coherent multi-year operating record. Accumulated deficit sits at -$7.14M and ROE is -300%. The only reason equity ($2.09M) and cash ($2.19M) jumped is the IPO, which contributed $3.24M of net proceeds in 2025 — that money is already being consumed: operating cash burn was $1.69M for the year, leaving barely over a year of runway before the company must raise again. Financing was further padded by $1.24M of stock issued for services, signaling a willingness to dilute shareholders to pay bills, and a $175K 'gain on debt settlement.'